Brentuximab vedotin

Nature Reviews Drug Discovery

Volumn 11, Issue 1, 2012, Pages 19-20

  Younes, Anas ^a   Yasothan, Uma ^b   Kirkpatrick, Peter ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b IQVIA   (United States)

^c Nature Reviews Drug Discovery ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; GEMTUZUMAB OZOGAMICIN; PREDNISOLONE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; LARGE CELL LYMPHOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIGENS, CD30; CLINICAL TRIALS, PHASE I AS TOPIC; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; LYMPHOMA, LARGE-CELL, ANAPLASTIC;

EID: 84855391703     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3629     Document Type: Article

References (10)

1. Alley, S. C, Okeley, N. M. & Senter, P. D. Antibody-drug conjugates: targeted drug delivery for cancer. Curr. Opin. Chem. Biol. 14, 529-537 (2010).
2. Younes, A. CD30-targeted antibody therapy. Curr. Opin. Oncol. 23, 587-593 (2011).
3. Wahl, A. F. et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res. 62, 3736-3742 (2002). (Pubitemid 34728855)
4. Francisco, J. A. et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102, 1458-1465 (2003). (Pubitemid 36988057)
5. Doronina, S. O. et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nature Biotech. 21, 778-784 (2003). (Pubitemid 36791396)
6. US Food and Drug Administration. FDA labeling information-Adcetris. FDA website [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 125388s000,125399s000lbl.pdf (2011).
7. Younes, A. et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med. 363, 1812-1821 (2010).
8. Bartlett, N. L. et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann. Oncol. 18, 1071-1079 (2007). (Pubitemid 47053777)
9. Gallamini, A. et al. Early interim 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J. Clin. Oncol. 25, 3746-3752 (2007). (Pubitemid 47372616)
10. Weihrauch, M. R. et al. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor. Cancer Res. 65, 5516-5519 (2005). (Pubitemid 40911150)